China’s National Medical Products Administration approved Carsgen Therapeutics’ satricabtagene autoleucel (satri-cel, CT-041), marking the first global approval of a CAR T therapy for solid tumors. The autologous, Claudin18.2-targeted therapy is indicated for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. Company-reported clinical data supported the decision, and Carsgen said the solid-tumor approval addresses a key historical hurdle for CAR T in solid malignancies. The company also described a preconditioning regimen combining low-dose nab-paclitaxel with lymphodepletion chemotherapy. The approval is notable for how it changes the deployment economics and clinical workflow expectations for CAR T in solid tumor settings, where prior development efforts struggled with safety complexity and limited efficacy durability. It also adds regulatory precedent for additional solid-tumor CAR T programs targeting solid-associated antigens. For the Chinese market, the nod extends cellular therapy beyond hematologic indications; for global developers, it raises the bar for differentiation across antigen choice, patient selection, and manufacturing feasibility.